Kamis, 27 September 2018

Curaizon — Revolutionizing the Pharmaceutical Industry with Big Data

Curaizon — Revolutionizing the Pharmaceutical Industry with Big Data


Screenshot_145.jpg



Introduction

The cost of some much-needed medication is often a big concern for national health services who are at times reluctant to pay the high prices charged for them. This means that some critically ill patients are given less effective medications that partly treat illness while causing numerous side effects — it is logical to suggest that this can lead to increased non-adherence. From a pharmaceutical company standpoint, high drug prices stem from the investments made in research and development (R&D) to develop new, more effective treatments for various diseases.
According to a recent report by the Tufts Center for the Study of Drug Development, the cost of developing a prescription drug that secures regulatory approval can reach an estimated USD 2.6 billion. A big reason for such a high cost in developing new drugs is the low levels of drug adherence seen presently as well as the related lack of data to inform of the reasons why. In fact, many pharmaceutical companies have seen their profits evaporate as a result.
Also, the disparity in accurate information often affects the reliability of research on the impact of medications leading to long and exhaustive testing processes. Another sticking point is the restricted access to relevant pieces of patient data for new drug development with factors including data protection, competition and non-standardized data. Curaizon, a pioneer of medical adherence technologies, is leveraging its blockchain-based technologies to provide the standardized, reliable and real-time big data needed by pharmaceutical companies, medical researchers and healthcare providers.

About Curaizon

Curaizon with its CuraData solution merges its patient adherence data with machine learning and AI technologies to develop unique, standardized and anonymized datasets that medical researchers and pharmaceutical companies can easily use. Through its data analytics tools, Curaizon aims to improve the quality and availability of real-time information. Its platform will generate datasets on adherence based on anonymized big data using its technologies to facilitate end-to-end data integration, a collaboration between different players in the healthcare sector, predictive modeling of the efficiency of different drugs to enhance clinical trial efficiency. Its adherence technology will also help improve understanding of the efficacy of drugs, something that is hard to achieve when adherence is estimated at only 50%.
CuraServe is where consumers will be able to use tokens and is essentially the patient database for consumers. It was created by national health services, and allows consumers to setup medication reminders, and may lower their overall cost of being treated for their condition.

Features Of The Platform

The Curaizon ecosystem consists of three key components: CuraServe, CuraView and CuraData.
CuraServe issues non-intrusive reminders to patients so that they take medication on time, while CuraView integrates with national health service systems. Using these technologies, Curaizon captures on average four data points for each patient every day. Unique demographic and adherence data on patients is collected and anonymized through CuraServe, stored and analyzed in CuraData. The data collected by Curaizon’s real-time adherence technologies can be merged with health provider-patient data to create even better and detailed datasets to further assist medicine research and development.
With the use of blockchain, the security, transparency and immutability of medical records can be ensured as access is restricted by the respective rules and storing points on blockchain.
As both patients and health services use Curaizon’s technologies, it creates opportunities to enhance the adherence data functionality and utility. In turn, data scientists, academics and researchers from pharmaceutical companies can overlay their own data with within CuraData to generate unique insights and further develop the ecosystem.

Token Exchange For Curaizon

The tokens used on Curaizon’s website will be referred to as CTKN, and holding these tokens lets users access the medical data collected. There is no other way to access the details of any medical information, and everything is posted on the blockchain in real-time.

Curaizon CuraToken CTKN Token ICO Details

Conclusion

By providing relevant real-time data, Curaizon will help pharmaceutical companies reduce their R&D costs, thereby bringing to market better quality medications quicker and more efficiently. In turn, this will lower the prices paid by patients and healthcare providers. Researchers will gain valuable insights into the shortcomings of existing treatments from patient feedback and real-time information on non-adherence as well as understand any complications that could be linked to a specific drug or form of treatment.
The goal of the Curaizon platform is to benefit both patients and providers in the health industry, which accounts for 1.4 billion people right now. The end goal is to continue development and make healthcare more affordable and less complicated for participants. This is a platform that could benefit the way consumers are treated, while minimizing visits to the doctor, if consumers are willing to put forth the effort.
NOTE: This article is just a guide to potential clients, stakeholders and everybody itching for a snip of this wonderful project and its published regarding bounty campaign. I am not a project team member or its representative but a supporter of this incredible project. The whitepaper will provide an in-depth and thorough analysis of this wonderful project. You can click on the link below and find out more about this wonderful project.
AUTHOR: tedotwijaya22
My Bitcointalk Profile Link: https://bitcointalk.org/index.php?action=profile;u=1928531
Diposting oleh di
Label:

Tidak ada komentar:

Posting Komentar

Langganan: Posting Komentar (Atom)